Grants and Contributions:
Title:
Development of degradable Cryoprotective Agents for Cell-based Therapies
Agreement Number:
1020999
Agreement Value:
$200,000.00
Agreement Date:
May 1, 2024 - Mar 31, 2025
Description:
Non-cell permeating microgels are developed to promote cryopreservation with limited or no use of DMSO. This project aims to develop degradable microgels that are easy to separate from cell suspensions post-thawing. The microgels are being developed to work with a wide variety of cells and cell clusters.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Dundas, Ontario, CA L9H 2E7
Reference Number:
172-2024-2025-Q2-1020999
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
735566085
Recipient Type:
For-profit organization
Recipient's Operating Name:
Allarta
Recipient's Legal Name:
Allarta Life Science Inc.
Federal Riding Name:
Hamilton West--Ancaster--Dundas
Federal Riding Number:
35038
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171